Anti-Human Beta Site APP Cleaving Enzyme (CT) (BACE) - 0.1 mg

Beta Site APP Cleaving Enzyme

Next Day Ambient

Accumulation of the amyloid-b (Ab) plaque in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. Ab peptide is generated by proteolytic cleavage of the b-amyloid protein precursor (APP) at b- and g-sites by two proteases. APP is first cleaved by b-secretase, producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for g-secretase to generate the 4 kDa amyloid-b peptide, which is deposited in the brains of all suffers of Alzheimer’s disease. The long-sought b-secretase was recently identified by several groups independently and designated β-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2).1-4 BACE/Asp2 is a novel transmembrane aspartic protease and colocalizes with APP.

Beta Site APP Cleaving Enzyme

AB_2828174

This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.